Targeted therapy for hormone receptor-positive breast cancer

page_title_detailed

About Breast Cancer>Treatments>Targeted therapy>Targeted therapy for hormone receptor-positive breast cancer > Everolimus

Everolimus

general_content

Everolimus (Afinitor) is a type of targeted therapy called an mTOR inhibitor, or a mammalian target of rapamycin inhibitor. It stops cancer cells from dividing and may block the growth of new blood vessels that tumors need to grow. Everolimus was the first mTOR inhibitor approved for treating metastatic breast cancer.

on_this_page

On this page

general_content

How everolimus works

mTOR is a protein kinase, a type of enzyme that helps control cell growth. In some cancers, mTOR-activated proteins work abnormally and encourage cancer cells to grow and spread. mTOR also directs nutrients to the cancer cells, helping to support them.

Everolimus works to slow or stop mTOR’s role in the growth of cancer cells. Paired with aromatase inhibitors like exemestane (Aromasin), everolimus slows cell growth by blocking nutrients and directions from mTOR, as well as the estrogen that encourages growth.

Back to top
general_content

Who gets everolimus

Everolimus is FDA approved for use with exemestane in postmenopausal women with metastatic, hormone receptor-positive, HER2-negative breast cancer that grows after treatment with aromatase inhibitors alone.

Back to top
general_content

How everolimus is given

Everolimus is a pill you can take by mouth once a day. You usually need to take it at the same time each day. Your doctor will recommend a specific dosage.

Back to top
general_content

Side effects and things to remember

Everolimus is an effective treatment but it has some possible serious side effects. When choosing treatments a treatment, you and your doctors should discuss how you can keep your quality of life high while you manage the disease.

Common side effects may include:

Less common side effects may include:

Before starting everolimus, be sure to tell your doctor about any medicines you are taking, including vitamins, herbal supplements and over the counter medicines.

You should avoid becoming pregnant while you are receiving everolimus. Tell your doctor right away if you become pregnant or may be pregnant while you are undergoing treatment.

Your doctor, pharmacist or nurse can help you manage your side effects. You can also go to our section on Side Effects for more information.

Back to top
related_resources_article_carousel

Related resources

Next-generation sequencing (NGS) tests

11/18/24 | BY: Pallav K. Mehta

Next-generation sequencing (NGS) is a testing technology that uses computers to look at hundreds of genes in cancer cells. The results can help guide treatment decisions.

Read More
 | 7 Min. Read

Immunohistochemistry (IHC) tests

11/15/24 | BY: Regina Hampton

Some of the most important breast cancer treatment decisions are based on immunohistochemistry (IHC) tests; hormone receptor status, HER2 status, and in some cases, PD-L1 status.

Read More
 | 7 Min. Read

FISH tests

11/15/24 | BY: Regina Hampton

A FISH test is a lab test performed on tissue taken from a biopsy or breast cancer surgery, that can confirm breast cancer’s HER2 status if other test results are inconclusive.

Read More
 | 5 Min. Read

Circulating tumor cell (CTC) tests

11/04/24 | BY: Lori B. Ranallo

Circulating tumor cell (CTC) tests can help monitor whether treatment is working or if breast cancer has metastasized.

Read More
 | 2 Min. Read

Treatment for metastatic breast cancer

10/14/24 | BY: Douglas Yee, Pallav K. Mehta

The goal of metastatic breast cancer treatment is to manage the disease while limiting side effects. Learn about available treatments and when they are used.

Read More
 | 22 Min. Read |

Targeted therapy for hormone receptor-positive breast cancer

10/14/24 | BY: Sameer Gupta, Pallav K. Mehta

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy, including CDK 4/6 inhibitors.

Read More
 | 12 Min. Read |

Clinical trials for MBC

09/26/24 | BY: Pallav K. Mehta

There are many reasons you might change treatments for metastatic breast cancer. If you and your doctors find that one medicine isn’t right for you anymore, you’ll talk about other therapies that are available.

Read More
 | 7 Min. Read |

Ribociclib

09/18/24 | BY: Sameer Gupta

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More
 | 6 Min. Read |

Diagnosed with metastatic breast cancer

07/29/24 | BY: Saveri Bhattacharya

Hearing the words “You have metastatic breast cancer, and you will need ongoing treatment” can be traumatic. On this page, we’ll help you begin to make sense of your diagnosis, treatment options, and sources of support.

Read More
 | 18 Min. Read |

Metastatic trial search

06/21/24

Use this tool to find metastatic breast cancer trials across the United States.

Read More
stay_connected

Stay connected

Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.

about_this_page_tabbed_module
About this page
Glossary
About LBBC

Reviewed and updated: August 31, 2015

Reviewed by: Kanu Sharan, MD

Tagged:

Was this page helpful?

Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.